A string of serious setbacks for possible treatments may be eroding researchers' -- and investors' -- confidence.
Unlike biotechs, many of these companies are pouring money into share buybacks -- instead of their long-term pipelines.
The only explanation for recent stock action is market players following others blindly. The bulls just have to hope analysts don't think this is National Lemming Week.
Investors are digesting a slew of earnings as they await jobless claims data.
With the sector stocks at all-time highs, analysts fear that investors will sell at first sign of trouble.
The sector's revaluation is on, and these names in particular have made some stunning moves.
Investors can still find some compelling valuations among large-cap drug companies even as major stock indices hit new highs.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The offering could become the second-biggest this year if underwriters exercise an option to buy more shares.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.